![]() |
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Fusion gene ID: 42818 |
FusionGeneSummary for ZFP36L2_SLAIN2 |
![]() |
Fusion gene information | Fusion gene name: ZFP36L2_SLAIN2 | Fusion gene ID: 42818 | Hgene | Tgene | Gene symbol | ZFP36L2 | SLAIN2 | Gene ID | 678 | 57606 |
Gene name | ZFP36 ring finger protein like 2 | SLAIN motif family member 2 | |
Synonyms | BRF2|ERF-2|ERF2|RNF162C|TIS11D | KIAA1458 | |
Cytomap | 2p21 | 4p11 | |
Type of gene | protein-coding | protein-coding | |
Description | mRNA decay activator protein ZFP36L2EGF-response factor 2TPA-induced sequence 11dZFP36-like 2butyrate response factor 2zinc finger protein 36, C3H type-like 1zinc finger protein 36, C3H type-like 2zinc finger protein 36, C3H1 type-like 2zinc finge | SLAIN motif-containing protein 2 | |
Modification date | 20180523 | 20180519 | |
UniProtAcc | P47974 | Q9P270 | |
Ensembl transtripts involved in fusion gene | ENST00000282388, | ENST00000264313, ENST00000506375, ENST00000512093, | |
Fusion gene scores | * DoF score | 3 X 3 X 2=18 | 3 X 3 X 1=9 |
# samples | 3 | 3 | |
** MAII score | log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(3/9*10)=1.73696559416621 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
Context | PubMed: ZFP36L2 [Title/Abstract] AND SLAIN2 [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ZFP36L2 | GO:0009611 | response to wounding | 27182009 |
Hgene | ZFP36L2 | GO:0044344 | cellular response to fibroblast growth factor stimulus | 20166898 |
Hgene | ZFP36L2 | GO:0070371 | ERK1 and ERK2 cascade | 25106868 |
Hgene | ZFP36L2 | GO:0071356 | cellular response to tumor necrosis factor | 20166898 |
Hgene | ZFP36L2 | GO:0071364 | cellular response to epidermal growth factor stimulus | 20166898 |
Hgene | ZFP36L2 | GO:0071385 | cellular response to glucocorticoid stimulus | 20166898 |
Hgene | ZFP36L2 | GO:0071560 | cellular response to transforming growth factor beta stimulus | 20166898 |
Hgene | ZFP36L2 | GO:0097011 | cellular response to granulocyte macrophage colony-stimulating factor stimulus | 20166898 |
![]() (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChiTaRS3.1 | AW080228 | ZFP36L2 | chr2 | 43449782 | + | SLAIN2 | chr4 | 48425613 | - |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
intron-3UTR | ENST00000282388 | ENST00000264313 | ZFP36L2 | chr2 | 43449782 | + | SLAIN2 | chr4 | 48425613 | - |
intron-intron | ENST00000282388 | ENST00000506375 | ZFP36L2 | chr2 | 43449782 | + | SLAIN2 | chr4 | 48425613 | - |
intron-3UTR | ENST00000282388 | ENST00000512093 | ZFP36L2 | chr2 | 43449782 | + | SLAIN2 | chr4 | 48425613 | - |
Top |
FusionProtFeatures for ZFP36L2_SLAIN2 |
![]() |
Hgene | Tgene |
ZFP36L2 | SLAIN2 |
Zinc-finger RNA-binding protein that destabilizesseveral cytoplasmic AU-rich element (ARE)-containing mRNAtranscripts by promoting their poly(A) tail removal ordeadenylation, and hence provide a mechanism for attenuatingprotein synthesis (PubMed:25106868, PubMed:14981510). Acts as a3'-untranslated region (UTR) ARE mRNA-binding adapter protein tocommunicate signaling events to the mRNA decay machinery(PubMed:25106868). Functions by recruiting the CCR4-NOTdeadenylase complex and probably other components of thecytoplasmic RNA decay machinery to the bound ARE-containing mRNAs,and hence promotes ARE-mediated mRNA deadenylation and decayprocesses (PubMed:25106868). Binds to 3'-UTR ARE of numerous mRNAs(PubMed:20506496, PubMed:25106868, PubMed:14981510). Promotes ARE-containing mRNA decay of the low-density lipoprotein (LDL)receptor (LDLR) mRNA in response to phorbol 12-myristate 13-acetate (PMA) treatment in a p38 MAPK-dependent manner(PubMed:25106868). Positively regulates early adipogenesis bypromoting ARE-mediated mRNA decay of immediate early genes (IEGs).Plays a role in mature peripheral neuron integrity by promotingARE-containing mRNA decay of the transcriptional repressor RESTmRNA. Plays a role in ovulation and oocyte meiotic maturation bypromoting ARE-mediated mRNA decay of the luteinizing hormonereceptor LHCGR mRNA. Acts as a negative regulator of erythroidcell differentiation: promotes glucocorticoid-induced self-renewalof erythroid cells by binding mRNAs that are induced or highlyexpressed during terminal erythroid differentiation and promotestheir degradation, preventing erythroid cell differentiation. Inassociation with ZFP36L1 maintains quiescence on developing Blymphocytes by promoting ARE-mediated decay of several mRNAsencoding cell cycle regulators that help B cells progress throughthe cell cycle, and hence ensuring accurate variable-diversity-joining (VDJ) recombination process and functional immune cellformation. Together with ZFP36L1 is also necessary for thymocytedevelopment and prevention of T-cell acute lymphoblastic leukemia(T-ALL) transformation by promoting ARE-mediated mRNA decay of theoncogenic transcription factor NOTCH1 mRNA.{ECO:0000250|UniProtKB:P23949, ECO:0000269|PubMed:14981510,ECO:0000269|PubMed:20506496, ECO:0000269|PubMed:25106868}. | Binds to the plus end of microtubules and regulatesmicrotubule dynamics and microtubule organization. Promotescytoplasmic microtubule nucleation and elongation. Required fornormal structure of the microtubule cytoskeleton duringinterphase. {ECO:0000269|PubMed:21646404}. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for ZFP36L2_SLAIN2 |
![]() (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for ZFP36L2_SLAIN2 |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for ZFP36L2_SLAIN2 |
![]() (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for ZFP36L2_SLAIN2 |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | ZFP36L2 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |